PCI Biotech Holding ASA Cash Flow Conversion Efficiency

Latest as of June 2025: -0.501x

PCI Biotech Holding ASA cash flow conversion efficiency. Based on the latest financial reports, PCI Biotech Holding ASA (PCIB) has a cash flow conversion efficiency ratio of -0.501x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-6.26 Million ≈ $-659.15K USD) by net assets (Nkr12.52 Million ≈ $1.32 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of PCI Biotech Holding ASA (2008–2024)

Cash flow conversion efficiency of PCI Biotech Holding ASA from 2008 to 2024. This chart illustrates how PCI Biotech Holding ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PCIB live share price for real-time trading data and today's change.

PCI Biotech Holding ASA Cash Flow Conversion Ratio Explained

PCI Biotech Holding ASA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

PCI Biotech Holding ASA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of PCI Biotech Holding ASA ranked by their cash flow conversion efficiency. Also see PCI Biotech Holding ASA (PCIB) market capitalisation for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Sino-German United AG
F:SGU
N/A
Portmeirion Group PLC
LSE:PMP
-0.015x
Ming Le Sports AG
F:ML2
-0.018x
Sejahtera Bintang Abadi Textile Tbk
JK:SBAT
-0.023x
Abingdon Health Plc
LSE:ABDX
-0.204x
Virpax Pharmaceuticals Inc
NASDAQ:VRPX
3.142x
HARVEST MINERALS LTD
F:7HM
N/A
Baltic Bridge S.A.
WAR:WIS
N/A

Annual Cash Flow Conversion Efficiency for PCI Biotech Holding ASA (2008–2024)

The table below shows the annual cash flow conversion efficiency of PCI Biotech Holding ASA from 2008 to 2024. Review PCI Biotech Holding ASA (PCIB) flexibility index to assess the company's free cash flow relative to its total liabilities.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 Nkr23.45 Million
≈ $2.47 Million
Nkr-13.76 Million
≈ $-1.45 Million
-0.587x -53.00%
2023-12-31 Nkr39.04 Million
≈ $4.11 Million
Nkr-14.97 Million
≈ $-1.58 Million
-0.383x +62.72%
2022-12-31 Nkr57.40 Million
≈ $6.04 Million
Nkr-59.04 Million
≈ $-6.21 Million
-1.029x -71.35%
2021-12-31 Nkr113.79 Million
≈ $11.97 Million
Nkr-68.31 Million
≈ $-7.19 Million
-0.600x -46.79%
2020-12-31 Nkr189.24 Million
≈ $19.91 Million
Nkr-77.39 Million
≈ $-8.14 Million
-0.409x -24.85%
2019-12-31 Nkr254.83 Million
≈ $26.82 Million
Nkr-83.47 Million
≈ $-8.78 Million
-0.328x -258.30%
2018-12-31 Nkr339.95 Million
≈ $35.77 Million
Nkr-31.08 Million
≈ $-3.27 Million
-0.091x +87.51%
2017-12-31 Nkr41.84 Million
≈ $4.40 Million
Nkr-30.62 Million
≈ $-3.22 Million
-0.732x +73.17%
2016-12-31 Nkr13.09 Million
≈ $1.38 Million
Nkr-35.69 Million
≈ $-3.76 Million
-2.728x -267.80%
2015-12-31 Nkr44.28 Million
≈ $4.66 Million
Nkr-32.84 Million
≈ $-3.46 Million
-0.742x +78.66%
2014-12-31 Nkr9.11 Million
≈ $959.06K
Nkr-31.67 Million
≈ $-3.33 Million
-3.475x -427.45%
2013-12-31 Nkr43.40 Million
≈ $4.57 Million
Nkr-28.59 Million
≈ $-3.01 Million
-0.659x -88.59%
2012-12-31 Nkr69.71 Million
≈ $7.34 Million
Nkr-24.35 Million
≈ $-2.56 Million
-0.349x -69.72%
2011-12-31 Nkr92.53 Million
≈ $9.74 Million
Nkr-19.05 Million
≈ $-2.00 Million
-0.206x -104.92%
2010-12-31 Nkr105.42 Million
≈ $11.09 Million
Nkr-10.59 Million
≈ $-1.11 Million
-0.100x +79.07%
2009-12-31 Nkr35.08 Million
≈ $3.69 Million
Nkr-16.84 Million
≈ $-1.77 Million
-0.480x -151.50%
2008-12-31 Nkr49.30 Million
≈ $5.19 Million
Nkr-9.41 Million
≈ $-990.10K
-0.191x --

About PCI Biotech Holding ASA

OL:PCIB Norway Biotechnology
Market Cap
$274.95K
Nkr2.61 Million NOK
Market Cap Rank
#31280 Global
#275 in Norway
Share Price
Nkr0.07
Change (1 day)
-39.13%
52-Week Range
Nkr0.07 - Nkr0.32
All Time High
Nkr86.30
About

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development of technologies and novel therapies through its photochemical technology platform. The company's technology platform consists of a proprietary small molecule photosensitiser and a light source; and develops photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vecto… Read more